secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0000950170-23-058509
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share
--------------------------------------------------------------------------------

- Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.
- GAAP net loss $13.1M ($0.44 EPS); non-GAAP loss $11.7M ($0.39 EPS) for Q3 2023.
- Adjusted EBITDA was $18.1M; cash from operations $10.2M in the quarter.
- Cash, cash equivalents, and marketable securities totaled $851M as of Sep 30, 2023.
- Fulgent reiterates full-year 2023 core revenue guidance of $260M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/0000950170-23-058509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023058509/flgt-20231103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer